LAG3 and breast cancer: However, MHC-II expression on BC cells exerts selection pressure on LAG-3+ and FCRL6+ TILs, antagonizing MHC-II expression and suppressing antigen presentation, which promotes adaptive resistance to anti-PD-1 therapy [174].